和遠氣體(002971.SZ):公司有信心實現2025年產值達到50億元的目標
格隆匯9月6日丨和遠氣體(002971.SZ)於2023年9月5日接受特定對象調研,就“請展望一下公司未來的業績?”,公司回覆稱,隨着公司兩大電子特氣和電子化學品產業園及其他工業氣體項目的建成投產,未來將形成電子特氣及電子化學品、硅基功能性新材料及大宗工業氣體三大版塊的齊頭並進,2023年和2024年公司有望實現良好的增長態勢,公司有信心實現2025年產值達到50億元的目標,具體請關注公司定期業績披露。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.